Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

APVO remained flat at $0.17 during trading on Friday. 435,134 shares of the company’s stock were exchanged, compared to its average volume of 2,507,124. Aptevo Therapeutics has a twelve month low of $0.14 and a twelve month high of $21.56. The business’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.92.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26. On average, sell-side analysts anticipate that Aptevo Therapeutics will post -4.3 earnings per share for the current year.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.